Population pharmacokinetics of erlotinib and its pharmacokinetic/pharmacodynamic relationships in head and neck squamous cell carcinoma

European Journal of Cancer

Volumn 45, Issue 13, 2009, Pages 2316-2323

  Thomas, Fabienne ^a,b   Rochaix, Philippe ^a,b   White Koning, Melanie ^a   Hennebelle, Isabelle ^a,b   Sarini, Jérôme ^b   Benlyazid, Adil ^b   Malard, Laurence ^b   Lefebvre, Jean Louis ^c   Chatelut, Etienne ^a,b   Delord, Jean Pierre ^a,b  

^a UNIVERSITÉ DE TOULOUSE   (France)

^b INSTITUT CLAUDIUS REGAUD   (France)

^c CENTRE OSCAR LAMBRET   (France)

Author keywords

Erlotinib; Head and neck; Pharmacogenetics; PK PD relationships; Population pharmacokinetics

Indexed keywords

ALANINE AMINOTRANSFERASE; BREAST CANCER RESISTANCE PROTEIN; CYTOCHROME P450 3A5; DRUG METABOLITE; ERLOTINIB; MULTIDRUG RESISTANCE PROTEIN 1; OSI 420; UNCLASSIFIED DRUG;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ERUPTION; DRUG EXPOSURE; DRUG WITHDRAWAL; FEMALE; HEAD AND NECK CARCINOMA; HUMAN; MALE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SQUAMOUS CELL CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; CARCINOMA, SQUAMOUS CELL; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM PROTEINS; PILOT PROJECTS; POLYMORPHISM, SINGLE NUCLEOTIDE; QUINAZOLINES;

EID: 68749095215     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2009.05.007     Document Type: Article

References (20)

1. Thomas F., Rochaix P., Benlyazid A., et al. Pilot study of neoadjuvant treatment with erlotinib in nonmetastatic head and neck squamous cell carcinoma. Clin Cancer Res 13 (2007) 7086-7092
2. Shepherd F.A., Rodrigues P.J., Ciuleanu T., et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353 (2005) 123-132
3. Moore M.J., Goldstein D., Hamm J., et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25 (2007) 1960-1966
4. Lu J.F., Eppler S.M., Wolf J., et al. Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non-small cell lung cancer. Clin Pharmacol Ther 80 (2006) 136-145
5. Li J., Zhao M., He P., Hidalgo M., and Baker S.D. Differential metabolism of gefitinib and erlotinib by human cytochrome p450 enzymes. Clin Cancer Res 13 (2007) 3731-3737
6. Li J., Cusatis G., Brahmer J., et al. Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients. Cancer Biol Ther 6 (2007) 432-438
7. Shi Z., Peng X.X., Kim I.W., et al. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance. Cancer Res 67 (2007) 11012-11020
8. Hidalgo M., Siu L.L., Nemunaitis J., et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 19 (2001) 3267-3279
9. Calvo E., Malik S.N., Siu L.L., et al. Assessment of erlotinib pharmacodynamics in tumors and skin of patients with head and neck cancer. Ann Oncol 18 (2007) 761-767
10. Soulieres D., Senzer N.N., Vokes E.E., et al. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 22 (2004) 77-85
11. Zhao M., He P., Rudek M.A., Hidalgo M., and Baker S.D. Specific method for determination of OSI-774 and its metabolite OSI-420 in human plasma by using liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 793 (2003) 413-420
12. Cascorbi I., Gerloff T., Johne A., et al. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther 69 (2001) 169-174
13. Yates C.R., Zhang W., Song P., et al. The effect of CYP3A5 and MDR1 polymorphic expression on cyclosporine oral disposition in renal transplant patients. J Clin Pharmacol 43 (2003) 555-564
14. Eberhard D.A., Johnson B.E., Amler L.C., et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 23 (2005) 5900-5909
15. Remmele W., and Stegner H.E. Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 8 (1987) 138-140
16. Miller A.A., Murry D.J., Owzar K., et al. Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101. J Clin Oncol 25 (2007) 3055-3060
17. Hamilton M., Wolf J.L., Rusk J., et al. Effects of smoking on the pharmacokinetics of erlotinib. Clin Cancer Res 12 (2006) 2166-2171
18. Hughes A.N., O'Brien M.E., Petty W.J., et al. Overcoming CYP1A1/1A2 mediated induction of metabolism by escalating erlotinib dose in current smokers. J Clin Oncol 27 (2009) 1220-1226
19. Chatelut E., Petain A., Azard J., et al. Population pharmacokinetics of imatinib in children and adults. ASCO Meeting Abstracts 26 (2008) 2526
20. Wacker B., Nagrani T., Weinberg J., et al. Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clin Cancer Res 13 (2007) 3913-3921